A Boston Sci spokesperson told MassDevice via email that the company has a practice of not commenting on speculation.
Boston Scientific acquired the antivenom business during its $4 billion acquisition of BTG, which closed last year. Its products include CroFab, touted as the only FDA-approved product exclusively derived from U.S. snakes. CroFab to date has treated more than 50,000 people suffering from bits from snakes including rattlesnakes, copperheads and cottonmouths/water moccasins.
The BTG acquisition also included devices for vascular and oncology applications, as well as drugs for treating overdoses.
Filed Under: Drug Discovery and Development